Scholars Central

Conference abstractPublished 15 Aug 2011

What is the optimal treatment for metastatic colorectal cancer?

Authors: Esther Una Cidon

Department of Oncology, Clinical University Hospital, SPAIN

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Colorectal cancer is the second leading cause of death from cancer in the developed countries. Although great efforts have been made to early diagnosis a relevant number of cases will present metastases. The natural history of metastatic Colorectal Cancer (mCRC) has dramatically evolved in the recent years thanks to the introduction of modern chemotherapy. Nowadays with the new drugs, such as oxaliplatin and irinotecan or modern drugs based on molecular targets (bevacizumab or cetuximab) the response rate has increased to 50% and the survival has been improved not only progression free survival, which has reached 12 months, but also overall survival which is longer than 2 years. Despite this progress many questions remain to be answered, mainly those related to the sequential regimens, drug rotation, alternant or intermitent schedules, optimal duration of chemotherapy, the role of maintenance chemotherapy and the role of doublets or triplets. The optimal duration of chemotherapy is very important because it has a direct influence on the patient quality of life, survival and costs. There are several studies addressing this topic and the alternatives we have, such as âÂ?Â?stop and goâÂ?, intermittent strategies or maintenance of only several agents and these studies reinforce the frequent behaviour of the oncologists to stop the treatment when the patient has obtained the maximum response. But there are some methodological problems in the analyzed trials which have determined that not all the professionals agree with this proposal. With this context it is essential to perform well designed clinical trials incorporating new drugs and addressing these questions. This presentation tries to review all these controversial points.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Esther Una Cidon”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels